Claims for Patent: 12,102,639

Summary for Patent: 12,102,639

Title:	Imipridones for gliomas
Abstract:	Imipridones selectively modulate Class A G protein-coupled receptors (GPCRs), such as the D2-like subfamily of dopamine receptors, and are useful for treating conditions and disorders in need of such modulation, such as cancers. Specifically, the cancer is a midline glioma, a cancer having a histone H3 mutation, or both. In addition, methods of identifying whether a subject having these conditions, is likely to be responsive to a treatment regimen, such as imipridone administration, are provided. Furthermore, methods of assessing the effectiveness of a treatment regimen, such as imipridone administration, monitoring, or providing a prognosis for a subject with these condition are also provided.
Inventor(s):	Joshua E. Allen, Martin Stogniew, Varun Vijay PRABHU
Assignee:	Oncoceutics Inc
Application Number:	US17/171,532
Patent Claims:	1. A method of treating a brain cancer in a patient in need thereof, the method comprising: administering to the patient a pharmaceutical composition comprising a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof, at a predetermined dose with a frequency selected from one or more of: a) once daily; b) according to an infrequent dosing regimen; c) according to a frequent dosing regimen; d) once weekly; e) once every four weeks; f) twice a week; g) once every two weeks; h) once every three weeks; and i) in a repeated cycle of once weekly, once every two weeks, once every three weeks, once every four weeks, wherein the cancer has a histone H3 K27M mutation. 2. The method of claim 1, wherein the cancer is of one or more of the thalamus, medulla, hypothalamus, basal ganglia, pineal gland, midbrain, cerebellum, pons, and spinal cord. 3. The method of claim 1, wherein the histone H3 K27M mutation is H3.3 K27M or H3.1 K27M. 4. The method of claim 1, wherein the histone H3 K27M mutation is in one or more histone genes selected from H3F3A, H3F3B, HIST1H3A, HIST1H3B, HIST1H3C, HIST1H3D, HIST1H3E, HIST1H3F, HIST1H3G, HIST1H3H, HIST1H3I, or HIST1H3J. 5. The method of claim 1, wherein in cancerous tissue DRD2 is overexpressed, DRD5 is underexpressed, or both. 6. The method of claim 1, wherein the brain cancer having a histone H3 mutation is selected from a paraganglioma, and a neuroendocrine tumor, or wherein the cancer comes from glial cells and is selected from meningioma, ependymoma, oligodendrogliomas, astrocytoma, optic nerve glioma, pineal tumors, rhabdoid tumors, and diffuse intrinsic pontine glioma; or wherein the cancer comes from neural cells and is selected from medulloblastoma, neuroblastoma, ganglioma, primitive neuroectodermal tumors, and schwannoma. 7. The method of claim 1, wherein the subject is a human. 8. The method of claim 1, wherein the subject is a pediatric subject. 9. The method of claim 1, wherein the subject is a domesticated pet. 10. The method of claim 1, wherein the compound is ONC201 (compound (1)) di-HCl. 11. The method of claim 1, wherein the predetermined dose is 625 mg. 12. A method of treating a brain cancer in a patient in need thereof, the method comprising: administering to the patient a pharmaceutical composition comprising: a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof, in a predetermined dose of about 5 mg/kg to about 10 mg/kg, based on patient weight; wherein the cancer has a histone H3 K27M mutation. 13. The method of claim 12, wherein the predetermined dose is 625 mg. 14. A method of treating a brain cancer in a patient in need thereof, the method comprising: administering to the patient a pharmaceutical composition comprising: a therapeutically effective amount of compound (1) or a pharmaceutically acceptable salt thereof, in a predetermined dose of about 280 mg/m to 330 mg/m2, based on patient body surface area; wherein the cancer has a histone H3 K27M mutation. 15. The method of claim 14, further comprising adjusting the predetermined dose to achieve higher inhibition of proteasomal activity. 16. The method of claim 14, wherein the dosage creates a Cmax of about 85 ng/dL to about 1500 ng/dL for a therapeutic time period. 17. The method of claim 14, wherein the pharmaceutical composition is administered to the patient in need thereof at a predetermined dose with a frequency selected from one or more of: a) once daily; b) according to an infrequent dosing regimen; c) according to a frequent dosing regimen; d) once weekly; e) once every four weeks; f) twice a week; g) once every two weeks; h) once every three weeks; and i) in a repeated cycle of once weekly, once every two weeks, once every three weeks, once every four weeks. 18. The method of claim 14, wherein the subject is a pediatric subject. 19. The method of claim 14, wherein the brain cancer having a histone H3 mutation is selected from a paraganglioma, and a neuroendocrine tumor, or wherein the cancer comes from glial cells and is selected from meningioma, ependymoma, oligodendrogliomas, astrocytoma, optic nerve glioma, pineal tumors, rhabdoid tumors, and diffuse intrinsic pontine glioma; or wherein the cancer comes from neural cells and is selected from medulloblastoma, neuroblastoma, ganglioma, primitive neuroectodermal tumors, and schwannoma.